Riverside’s private equity

News Release

Riverside Fills Kneed at Global Ortho April 05, 2017

Global Orthopaedic Technology Acquires the Apex Knee Implant

The Riverside Company platform Global Orthopaedic Technology (GOT) has acquired the license for the Apex fixed-bearing knee implant (Apex) for Australia, New Zealand and South Africa from Omni Life Sciences Inc.

GOT is an Australian manufacturer and distributor of orthopaedic implants. It primarily supplies implants and instrumentation for hip and knee surgeries, along with related orthobiologics. Apex is the largest distributed product for GOT, accounting for approximately 40% of the company’s total product portfolio sales.

“The addition of the Apex results in GOT becoming an almost entirely sovereign product business,” said Riverside Partner Steven Spiteri. “This has a been key strategy for GOT ever since our investment in 2014 and will assist GOT in becoming a larger and more capable business while giving it more control over its supply chain and its future.”

Senior Associate Kevin Xu worked with Spiteri on the transaction for Riverside.

Kardos Scanlan provided legal advice to GOT on the transaction.

The Riverside Company

The Riverside Company is a global private equity firm focused on making control and non-control investments in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has invested in more than 460 transactions. The firm’s international portfolio includes more than 80 companies.

Media Contact

Stephanie Fraser
Marketing Consultant
The Riverside Company
Cleveland: +1 216 344 1267
London: +44 20 3077 1923